Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552857677> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2552857677 abstract "Abstract Introduction : Novel non-surgical options for treatment of chronic immune thrombocytopenic purpura (ITP) are emerging. These include rituximab, an anti-CD20 monoclonal antibody, and romiplostim, a soon to be approved thrombopoeitic receptor agonist. However, long-term clinical data with these agents have not been reported previously and the cost of romiplostim treatment has not been announced. Herein, we report a “break-even” cost-effectiveness analysis, based on 2.5 years clinical outcome data for both agents, which yields a suggested market cost for romiplostim that would result in equivalent cost-effectiveness profiles for the two agents when administered as treatment for chronic ITP. Methods: Effectiveness data were based on 2.5-years results from studies of chronic ITP patients treated with rituximab or romiplostim. We calculated the total costs of treating a cohort of chronic ITP patients with ritiuxan with splenectomy salvage (estimated cost of $8,100) as the therapeutic choice for treatment failures. We subsequently calculated a break-even price for romiplostin with splenectomy salvage that would result in a total cost of treating an ITP cohort equivalent to the costs of treating the rituximab/splenectomy cohort. Results: At 2.5 years follow-up, a cohort of 100 chronic ITP patients initially treated with rituximab is associated with 40 therapeutic failures going on to splenectomy annually. Total treatment costs for this cohort is estimated at $2.2 million. At 2.5 years follow-up, a cohort of 100 chronic ITP patients initially treated with romiplostim is associated with 10 splenectomy failures per year. Total 2.5 year treatment costs for this cohort is $1.9 million for splenectomy plus the costs of treating 70 ITP patients with romiplastim for 2.5 years, 20 ITP patients for two years, and 10 ITP patients for one year. Hence, annual break-even costs for romipslatim are estimated at $20,000. The higher annual cost with romiplostim versus rituximab is related to better 2.5 year outcome rates. Hence, these cost estimates are preliminary, pending reporting of additional long-term studies. Conclusions: It will be of interest to compare this value with cost-effectiveness estimates that are based on actual pricing of romiplostim (when the drug receives FDA approval). Policy makers would be wise to develop break-even cost estimates for novel drugs prior to FDA approval. These analyses may help inform initial price setting efforts." @default.
- W2552857677 created "2016-11-30" @default.
- W2552857677 creator A5019508460 @default.
- W2552857677 creator A5036848051 @default.
- W2552857677 creator A5037456539 @default.
- W2552857677 creator A5055145323 @default.
- W2552857677 creator A5062688748 @default.
- W2552857677 creator A5078727352 @default.
- W2552857677 date "2008-11-16" @default.
- W2552857677 modified "2023-10-01" @default.
- W2552857677 title "A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim." @default.
- W2552857677 doi "https://doi.org/10.1182/blood.v112.11.3433.3433" @default.
- W2552857677 hasPublicationYear "2008" @default.
- W2552857677 type Work @default.
- W2552857677 sameAs 2552857677 @default.
- W2552857677 citedByCount "1" @default.
- W2552857677 crossrefType "journal-article" @default.
- W2552857677 hasAuthorship W2552857677A5019508460 @default.
- W2552857677 hasAuthorship W2552857677A5036848051 @default.
- W2552857677 hasAuthorship W2552857677A5037456539 @default.
- W2552857677 hasAuthorship W2552857677A5055145323 @default.
- W2552857677 hasAuthorship W2552857677A5062688748 @default.
- W2552857677 hasAuthorship W2552857677A5078727352 @default.
- W2552857677 hasConcept C109159458 @default.
- W2552857677 hasConcept C121332964 @default.
- W2552857677 hasConcept C126322002 @default.
- W2552857677 hasConcept C142424586 @default.
- W2552857677 hasConcept C2776309230 @default.
- W2552857677 hasConcept C2776915898 @default.
- W2552857677 hasConcept C2777863708 @default.
- W2552857677 hasConcept C2779338263 @default.
- W2552857677 hasConcept C2779771385 @default.
- W2552857677 hasConcept C2780588981 @default.
- W2552857677 hasConcept C2780653079 @default.
- W2552857677 hasConcept C2780931953 @default.
- W2552857677 hasConcept C28328180 @default.
- W2552857677 hasConcept C2993327898 @default.
- W2552857677 hasConcept C54355233 @default.
- W2552857677 hasConcept C71924100 @default.
- W2552857677 hasConcept C72563966 @default.
- W2552857677 hasConcept C86803240 @default.
- W2552857677 hasConcept C87355193 @default.
- W2552857677 hasConcept C89560881 @default.
- W2552857677 hasConceptScore W2552857677C109159458 @default.
- W2552857677 hasConceptScore W2552857677C121332964 @default.
- W2552857677 hasConceptScore W2552857677C126322002 @default.
- W2552857677 hasConceptScore W2552857677C142424586 @default.
- W2552857677 hasConceptScore W2552857677C2776309230 @default.
- W2552857677 hasConceptScore W2552857677C2776915898 @default.
- W2552857677 hasConceptScore W2552857677C2777863708 @default.
- W2552857677 hasConceptScore W2552857677C2779338263 @default.
- W2552857677 hasConceptScore W2552857677C2779771385 @default.
- W2552857677 hasConceptScore W2552857677C2780588981 @default.
- W2552857677 hasConceptScore W2552857677C2780653079 @default.
- W2552857677 hasConceptScore W2552857677C2780931953 @default.
- W2552857677 hasConceptScore W2552857677C28328180 @default.
- W2552857677 hasConceptScore W2552857677C2993327898 @default.
- W2552857677 hasConceptScore W2552857677C54355233 @default.
- W2552857677 hasConceptScore W2552857677C71924100 @default.
- W2552857677 hasConceptScore W2552857677C72563966 @default.
- W2552857677 hasConceptScore W2552857677C86803240 @default.
- W2552857677 hasConceptScore W2552857677C87355193 @default.
- W2552857677 hasConceptScore W2552857677C89560881 @default.
- W2552857677 hasLocation W25528576771 @default.
- W2552857677 hasOpenAccess W2552857677 @default.
- W2552857677 hasPrimaryLocation W25528576771 @default.
- W2552857677 hasRelatedWork W1860521168 @default.
- W2552857677 hasRelatedWork W1981122966 @default.
- W2552857677 hasRelatedWork W2029872049 @default.
- W2552857677 hasRelatedWork W2042188395 @default.
- W2552857677 hasRelatedWork W2052625449 @default.
- W2552857677 hasRelatedWork W2352796693 @default.
- W2552857677 hasRelatedWork W2375840196 @default.
- W2552857677 hasRelatedWork W2531679557 @default.
- W2552857677 hasRelatedWork W2554151492 @default.
- W2552857677 hasRelatedWork W2557510417 @default.
- W2552857677 hasRelatedWork W2562704135 @default.
- W2552857677 hasRelatedWork W2564101856 @default.
- W2552857677 hasRelatedWork W2615717169 @default.
- W2552857677 hasRelatedWork W2794975738 @default.
- W2552857677 hasRelatedWork W3011912631 @default.
- W2552857677 hasRelatedWork W3013184390 @default.
- W2552857677 hasRelatedWork W2128721688 @default.
- W2552857677 hasRelatedWork W2226763728 @default.
- W2552857677 hasRelatedWork W2899112129 @default.
- W2552857677 hasRelatedWork W2899344264 @default.
- W2552857677 isParatext "false" @default.
- W2552857677 isRetracted "false" @default.
- W2552857677 magId "2552857677" @default.
- W2552857677 workType "article" @default.